Financial Survey: RAPT Therapeutics (RAPT) & Its Rivals
RAPT Therapeutics (NASDAQ: RAPT) is one of 611 public companies in the “Pharmaceutical preparations” industry, but how does it contrast to its rivals? We will compare RAPT Therapeutics to similar companies based on the strength of its institutional ownership, profitability, analyst recommendations, valuation, earnings, dividends and risk.
Valuation & Earnings
This table compares RAPT Therapeutics and its rivals gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|RAPT Therapeutics||N/A||-$43.00 million||-1.58|
|RAPT Therapeutics Competitors||$2.13 billion||$268.21 million||0.02|
This is a breakdown of current ratings and price targets for RAPT Therapeutics and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|RAPT Therapeutics Competitors||6512||18018||35008||1396||2.51|
RAPT Therapeutics currently has a consensus price target of $37.50, suggesting a potential upside of 140.69%. As a group, “Pharmaceutical preparations” companies have a potential upside of 38.41%. Given RAPT Therapeutics’ stronger consensus rating and higher possible upside, equities analysts clearly believe RAPT Therapeutics is more favorable than its rivals.
This table compares RAPT Therapeutics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|RAPT Therapeutics Competitors||-2,784.45%||-234.83%||-32.32%|
Insider & Institutional Ownership
34.1% of RAPT Therapeutics shares are held by institutional investors. Comparatively, 45.0% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 15.8% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
About RAPT Therapeutics
RAPT Therapeutics, Inc., a clinical stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. The company develops small molecules that are designed to modulate the critical immune responses underlying these diseases. Its lead oncology drug candidate is FLX475 for the treatment of a range of tumors; and RPT193, a CCR4 antagonist for allergic inflammatory disease. The company is also pursuing a range of targets, including general control nonderepressible and hematopoietic progenitor kinase for the treatment of cancer. RAPT Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company.
Receive News & Ratings for RAPT Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RAPT Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.